ArticleNeurology(R) neuroimmunology & neuroinflammation2019
Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.BMC neurology · 2024Pooled it
- Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Trial
- MRI-Based Quantitative Assessment of Normal-Appearing White and Gray Matter Demyelination in Multiple Sclerosis, Parkinson's Disease, Long COVID, and Normal Aging.Biomedicines · 2026Article
- Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms.Expert review of neurotherapeutics · 2025Review
- Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis: An Association With Disease Progression.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Automated Quantitative Susceptibility and Morphometry MR Study: Feasibility and Interrelation Between Clinical Score, Lesion Load, Deep Grey Matter and Normal-Appearing White Matter in Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Article
- The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse?Journal of neuroinflammation · 2024Review
- U-fiber diffusion kurtosis and susceptibility characteristics in relapsing-remitting multiple sclerosis may be related to cognitive deficits and neurodegeneration.European radiology · 2024Article
- MicroRNAs dysregulated in multiple sclerosis affect the differentiation of CG-4 cells, an oligodendrocyte progenitor cell line.Frontiers in cellular neuroscience · 2024Article
- Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.Frontiers in immunology · 2023Review
- Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy.Annals of clinical and translational neurology · 2022Article
- Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.JAMA neurology · 2022Observational
- Connecting Neuroinflammation and Neurodegeneration in Multiple Sclerosis: Are Oligodendrocyte Precursor Cells a Nexus of Disease?Frontiers in cellular neuroscience · 2021Review
- Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Vitamin D deficiency and its association with fatigue and quality of life in multiple sclerosis patients.The EPMA journal · 2020Article
- Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials.The EPMA journal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the combined effect of lesion activity and pathologic processes occurring in both chronically demyelinated lesions and normal-appearing white matter (NAWM) on brain atrophy in MS.
methodsPre- and post-gadolinium T1, fluid attenuation inversion recovery, and diffusion tensor imaging images were acquired from 50 consecutive patients with relapsing-remitting MS (all, but one, on disease-modifying therapy) at baseline and 5 years. Brain atrophy was measured using structural image evaluation, using normalization of atrophy percent brain volume change (PBVC) analysis.
resultsDuring follow-up, brain volume diminished by 2.0% ± 1.1%. PBVC was not associated with patient age, disease duration, sex, or type of treatment. PBVC moderately correlated with baseline lesion load (
conclusionIn addition to new lesion activity, progressive loss of demyelinated axons in chronic lesions and the degree of demyelination in NAWM significantly contribute to accelerated loss of brain tissue in patients with MS receiving immunomodulatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.